Eosinophilic esophagitis in the “atopic march”: dupilumab as an “umbrella” strategy for multiple coexisting atopic diseases
Dupilumab is a monoclonal antibody targeting interleukin-4 and interleukin-13, approved for the treatment of multiple T2 diseases and more recently for Eosinophilic Esophagitis (EoE). EoE is a chronic T2 inflammatory disease, believed to be a member of the “atopic march”, due to multiple similaritie...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1513417/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592401343971328 |
|---|---|
| author | Nicola Lutzu Nicola Lutzu Agnese Favale Mauro Demurtas Stefano Del Giacco Stefano Del Giacco Sara Onali Sara Onali Massimo Claudio Fantini Massimo Claudio Fantini |
| author_facet | Nicola Lutzu Nicola Lutzu Agnese Favale Mauro Demurtas Stefano Del Giacco Stefano Del Giacco Sara Onali Sara Onali Massimo Claudio Fantini Massimo Claudio Fantini |
| author_sort | Nicola Lutzu |
| collection | DOAJ |
| description | Dupilumab is a monoclonal antibody targeting interleukin-4 and interleukin-13, approved for the treatment of multiple T2 diseases and more recently for Eosinophilic Esophagitis (EoE). EoE is a chronic T2 inflammatory disease, believed to be a member of the “atopic march”, due to multiple similarities with other atopic diseases, ranging from epidemiology to genetics and pathophysiology. Although often co-existing in the same patient, these diseases are still treated as separated entities by different specialists, resulting in polypharmacy and chronic use of steroids. Thus, a shared-decision approach by a multidisciplinary team composed of different specialists might improve clinical management and outcomes. Yet, prospective data on the effectiveness of dupilumab as a single agent for multiple T2 inflammatory diseases are lacking, since only few case reports and small studies have been published so far reporting outcomes in patients affected by multiple T2 diseases. The purpose of this review is to illustrate the rationale and clinical evidence supporting the possibility of using dupilumab as a single therapeutic agent in those patients affected by multiple T2 diseases in addition to EoE. |
| format | Article |
| id | doaj-art-22991ff645f64883ae07520709734ccf |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-22991ff645f64883ae07520709734ccf2025-01-21T08:36:34ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-01-011110.3389/fmed.2024.15134171513417Eosinophilic esophagitis in the “atopic march”: dupilumab as an “umbrella” strategy for multiple coexisting atopic diseasesNicola Lutzu0Nicola Lutzu1Agnese Favale2Mauro Demurtas3Stefano Del Giacco4Stefano Del Giacco5Sara Onali6Sara Onali7Massimo Claudio Fantini8Massimo Claudio Fantini9Department of Medical Science and Public Health, University of Cagliari, Cagliari, ItalyAzienda Ospedaliero-Universitaria di Cagliari, Cagliari, ItalyDepartment of Medical Science and Public Health, University of Cagliari, Cagliari, ItalyAzienda Ospedaliero-Universitaria di Cagliari, Cagliari, ItalyDepartment of Medical Science and Public Health, University of Cagliari, Cagliari, ItalyAzienda Ospedaliero-Universitaria di Cagliari, Cagliari, ItalyDepartment of Medical Science and Public Health, University of Cagliari, Cagliari, ItalyAzienda Ospedaliero-Universitaria di Cagliari, Cagliari, ItalyDepartment of Medical Science and Public Health, University of Cagliari, Cagliari, ItalyAzienda Ospedaliero-Universitaria di Cagliari, Cagliari, ItalyDupilumab is a monoclonal antibody targeting interleukin-4 and interleukin-13, approved for the treatment of multiple T2 diseases and more recently for Eosinophilic Esophagitis (EoE). EoE is a chronic T2 inflammatory disease, believed to be a member of the “atopic march”, due to multiple similarities with other atopic diseases, ranging from epidemiology to genetics and pathophysiology. Although often co-existing in the same patient, these diseases are still treated as separated entities by different specialists, resulting in polypharmacy and chronic use of steroids. Thus, a shared-decision approach by a multidisciplinary team composed of different specialists might improve clinical management and outcomes. Yet, prospective data on the effectiveness of dupilumab as a single agent for multiple T2 inflammatory diseases are lacking, since only few case reports and small studies have been published so far reporting outcomes in patients affected by multiple T2 diseases. The purpose of this review is to illustrate the rationale and clinical evidence supporting the possibility of using dupilumab as a single therapeutic agent in those patients affected by multiple T2 diseases in addition to EoE.https://www.frontiersin.org/articles/10.3389/fmed.2024.1513417/fullesophagitisatopic marchanti-IL4anti-IL13eosinophilsdupilumab |
| spellingShingle | Nicola Lutzu Nicola Lutzu Agnese Favale Mauro Demurtas Stefano Del Giacco Stefano Del Giacco Sara Onali Sara Onali Massimo Claudio Fantini Massimo Claudio Fantini Eosinophilic esophagitis in the “atopic march”: dupilumab as an “umbrella” strategy for multiple coexisting atopic diseases Frontiers in Medicine esophagitis atopic march anti-IL4 anti-IL13 eosinophils dupilumab |
| title | Eosinophilic esophagitis in the “atopic march”: dupilumab as an “umbrella” strategy for multiple coexisting atopic diseases |
| title_full | Eosinophilic esophagitis in the “atopic march”: dupilumab as an “umbrella” strategy for multiple coexisting atopic diseases |
| title_fullStr | Eosinophilic esophagitis in the “atopic march”: dupilumab as an “umbrella” strategy for multiple coexisting atopic diseases |
| title_full_unstemmed | Eosinophilic esophagitis in the “atopic march”: dupilumab as an “umbrella” strategy for multiple coexisting atopic diseases |
| title_short | Eosinophilic esophagitis in the “atopic march”: dupilumab as an “umbrella” strategy for multiple coexisting atopic diseases |
| title_sort | eosinophilic esophagitis in the atopic march dupilumab as an umbrella strategy for multiple coexisting atopic diseases |
| topic | esophagitis atopic march anti-IL4 anti-IL13 eosinophils dupilumab |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2024.1513417/full |
| work_keys_str_mv | AT nicolalutzu eosinophilicesophagitisintheatopicmarchdupilumabasanumbrellastrategyformultiplecoexistingatopicdiseases AT nicolalutzu eosinophilicesophagitisintheatopicmarchdupilumabasanumbrellastrategyformultiplecoexistingatopicdiseases AT agnesefavale eosinophilicesophagitisintheatopicmarchdupilumabasanumbrellastrategyformultiplecoexistingatopicdiseases AT maurodemurtas eosinophilicesophagitisintheatopicmarchdupilumabasanumbrellastrategyformultiplecoexistingatopicdiseases AT stefanodelgiacco eosinophilicesophagitisintheatopicmarchdupilumabasanumbrellastrategyformultiplecoexistingatopicdiseases AT stefanodelgiacco eosinophilicesophagitisintheatopicmarchdupilumabasanumbrellastrategyformultiplecoexistingatopicdiseases AT saraonali eosinophilicesophagitisintheatopicmarchdupilumabasanumbrellastrategyformultiplecoexistingatopicdiseases AT saraonali eosinophilicesophagitisintheatopicmarchdupilumabasanumbrellastrategyformultiplecoexistingatopicdiseases AT massimoclaudiofantini eosinophilicesophagitisintheatopicmarchdupilumabasanumbrellastrategyformultiplecoexistingatopicdiseases AT massimoclaudiofantini eosinophilicesophagitisintheatopicmarchdupilumabasanumbrellastrategyformultiplecoexistingatopicdiseases |